Should I Buy BFRG? BFRG 2026 Analysis

Should You Buy Bullfrog AI Holdings Inc (BFRG) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.640

1 Day change

-7.03%

52 Week Range

4.840

Analysis Updated At

2026/01/28

BFRG is not a good buy right now for a Beginner, long-term investor with $50k–$100k who is unwilling to wait for an optimal entry. The stock is in a bearish trend (long-term moving averages stacked bearishly) and the business is still posting widening losses with no near-term catalysts. With no proprietary buy signals active today, the risk/reward is unattractive for a long-term, beginner-focused allocation. Action: sell/avoid new buying now.

Technical Analysis

Price/Trend: Current price ~0.729 (flat on regular session; +3.28% pre-market). Trend remains bearish because SMA_200 > SMA_20 > SMA_5, indicating the stock is below key longer-term averages and downward-biased. Momentum: MACD histogram is positive (0.0046) but positively contracting—suggests the prior bullish momentum is fading rather than strengthening. RSI(6) at ~41 is neutral-to-weak (not oversold), so there is no strong mean-reversion buy signal. Levels: Pivot 0.729. Support at 0.662 (S1) then 0.621 (S2). Resistance at 0.796 (R1) then 0.837 (R2). Given the bearish MA structure, rallies toward 0.796–0.837 are more likely to face selling pressure than confirm a breakout. Pattern-based short-term odds (provided): modest expected moves (next day ~2.23% upside probability 50%), but this is not a long-term edge and doesn’t offset weak fundamentals. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

Pre-market strength (+3.28%) suggests some near-term buying interest.
MACD histogram is still above zero, implying residual upside momentum may linger.
Clear nearby support zone (0.662–0.621) may limit downside in the very short term if buyers defend it.

Neutral/Negative Catalysts

Primary trend is bearish (SMA_200 > SMA_20 > SMA_5), which typically works against long-term entries.
No news in the past week—no identified event-driven catalyst to change the narrative.
Trading trends: hedge funds neutral; insiders neutral—no strong “smart money” confirmation.
Short-term pattern forecast indicates only small expected gains over week/month, not compelling for a long-term allocation.
Losses are worsening YoY (net income and EPS down), which is a negative backdrop for sustained re-rating.

Financial Performance

Latest reported quarter: 2025/Q3. Revenue: 83,413 (up 0.00% YoY — essentially flat at a very low base). Net Income: -1,551,612 (down -12.01% YoY — losses widened). EPS: -0.15 (down -31.82% YoY — per-share losses worsened). Gross Margin: 18.43 (up 0.00% YoY — flat). Overall: No meaningful revenue growth and deteriorating profitability trend in 2025/Q3, which is unfavorable for a long-term beginner investor seeking steadier compounding.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price-target trend data was provided, so a Wall Street consensus view cannot be confirmed from the dataset. Pros (typical if covered): AI/biotech angle can attract thematic interest. Cons: Lack of demonstrated growth and worsening losses make it difficult for analysts to justify sustained upside without a clear catalyst or improving financial trajectory. Influential/Politician activity: No recent congress trading data available (and no politician transaction data provided).

Analyst Rating

Wall Street analysts forecast BFRG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFRG is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold